

## Conference Learning Objectives

- Analyze the latest advancements in cardiovascular and metabolic disease
- Interpret and apply current cardiovascular guidelines
- Evaluate clinical trial results and their impact on patient care

## Conference Date & Time

**SESSION 1** Wednesday, June 3rd (7:00 - 9:00 pm EDT)

**SESSION 2** Wednesday, June 10th (7:00 - 9:00 pm EDT)

**SESSION 3** Wednesday, June 17th (7:00 - 9:00 pm EDT)

## Conference Co-Chairs



### Milan Gupta

MD, FRCPC, FCCS, CPC(HC)  
Assistant Professor,  
Department of Medicine,  
University of Toronto  
Medical Director,  
Collaborative CME & Research Network  
Brampton, ON



### Liam Brunham

MD, PhD, FRCPC, FNLA  
University of British Columbia  
Internal Medicine Specialist -Lipids  
Vancouver, BC

## Program Agenda

## Faculty

### SESSION 1 - Wednesday, June 3rd (7:00-9:00 pm EDT)

- 7:00 PM **Welcome and Introductions**
- 7:10 PM Gender differences in CV risk factors, disease and management TBC
- 7:30 PM Workup and treatment of resistant hypertension TBC
- 7:50 PM Are we under-treating chronic kidney disease? TBC
- 8:10 PM HFrEF diagnosis and management in primary care TBC
- 8:30 PM Q&A
- 9:00 PM **Closing Comments**

### SESSION 2 - Wednesday, June 10th (7:00-9:00 pm EDT)

- 7:00 PM **Welcome and Introductions**
- 7:10 PM Detection and management of ATTR in primary care TBC
- 7:30 PM What you need to know about metabolic dysfunction-associated steatotic liver disease (MASLD) TBC
- 7:50 PM GLP-1 therapies: applications in cardiovascular disease Milan Gupta
- 8:10 PM New frontiers: Will CV inflammation be a treatment target? TBC
- 8:30 PM Q&A
- 9:00 PM **Closing Comments**

### SESSION 3 - Wednesday, June 17th (7:00-9:00 pm EDT)

- 7:00 PM **Welcome and Introductions**
- 7:10 PM Where does bempedoic acid fit in my practice? Liam Brunham
- 7:30 PM Prompt LDL-reduction post-MI: applying new guidelines to clinical practice TBC
- 7:50 PM New frontiers: Where will oral PCSK9 inhibitors fit in clinical practice Milan Gupta
- 8:10 PM New frontiers: Will Lp(a) be a treatment target? TBC
- 8:30 PM Q&A
- 9:00 PM **Closing Comments**



**Register Now** →

Visit at: [www.ccrnmd.com](http://www.ccrnmd.com)

This program has received unrestricted educational funding support from:

🏆 **Gold:** Amgen, AstraZeneca  
🏆 **Bronze:** Bayer, Merck

For inquiries regarding this program, please contact [info@ccrnmd.com](mailto:info@ccrnmd.com)

# Program Agenda

Time	Topic	Learning Objective	Faculty
<b>SESSION 1 - Wednesday, June 3rd (7:00-9:00 pm EDT)</b>			
7:00 - 7:10 PM	<b>Welcome and Introductions</b>		
7:10 - 7:30 PM	Gender differences in CV risk factors, disease and management	Recognize sex-related differences in cardiovascular risk, presentation, and treatment outcomes to improve prevention and management	TBC
7:30 - 7:50 PM	Workup and treatment of resistant hypertension	Identify patients with resistant hypertension and evaluate the role of the aldosterone pathway and emerging targeted therapies	TBC
7:50 - 8:10 PM	Are we under-treating chronic kidney disease?	Recognize chronic kidney disease in patients at cardiovascular risk and apply evidence-based therapies that reduce cardiovascular events and slow disease progression	TBC
8:10 - 8:30 PM	HFpEF diagnosis and management in primary care	Recognize HFpEF in primary care and apply current diagnostic strategies and therapies that improve patient outcomes	TBC
8:30 - 9:00 PM	Q&A		
9:00 PM	<b>Closing Comments</b>		
<b>SESSION 2 - Wednesday, June 10th (7:00-9:00 pm EDT)</b>			
7:10 - 7:10 PM	<b>Welcome and Introductions</b>		
7:10 - 7:30 PM	Detection and management of ATTR in primary care	Identify clinical features that should prompt evaluation for transthyretin amyloidosis and initiate appropriate referral and management pathways	TBC
7:30 - 7:50 PM	What you need to know about metabolic dysfunction-associated steatotic liver disease (MASLD)	Recognize the link between MASLD and cardiovascular risk and apply cardiometabolic risk-reduction strategies	TBC
7:50 - 8:10 PM	GLP-1 therapies: applications in cardiovascular disease	Apply cardiovascular outcomes evidence for GLP-1 receptor agonists to reduce cardiovascular risk in patients with obesity or cardiometabolic disease	Milan Gupta



**Register Now** →

Visit at: [www.ccrnmd.com](http://www.ccrnmd.com)

This program has received unrestricted educational funding support from:

- 🏆 **Gold:** Amgen, AstraZeneca
- 🏆 **Bronze:** Bayer, Merck

For inquiries regarding this program, please contact [info@ccrnmd.com](mailto:info@ccrnmd.com)



# Program Agenda

Time	Topic	Learning Objective	Faculty
<b>SESSION 2 - Wednesday, June 10th (7:00-9:00 pm EDT)</b>			
8:10 - 8:30 PM	New frontiers: Will CV inflammation be a treatment target?	Evaluate emerging evidence linking inflammation to cardiovascular disease and its potential implications for future patient care	TBC
8:30 - 9:00 PM	Q&A		
9:00 PM	<b>Closing Comments</b>		



<b>SESSION 3 - Wednesday, June 17th (7:00-9:00 pm EDT)</b>			
7:00 - 7:10 PM	<b>Welcome and Introductions</b>		
7:10 - 7:30 PM	Where does bempedoic acid fit in my practice?	Apply recent evidence to determine when bempedoic acid should be added to lipid-lowering therapy	Liam Brunham
7:30 - 7:50 PM	Prompt LDL-reduction post-MI: applying new guidelines to clinical practice	Apply current guideline recommendations to achieve rapid and sustained LDL-C reduction following myocardial infarction	TBC
7:50 - 8:10 PM	New frontiers: Where will oral PCSK9 inhibitors fit in clinical practice	Evaluate emerging evidence for oral PCSK9-targeting therapies and their potential role in lipid management	Milan Gupta
8:10 - 8:30 PM	New frontiers: Will Lp(a) be a treatment target?	Recognize the role of lipoprotein(a) in cardiovascular risk and evaluate emerging therapies targeting Lp(a)	TBC
8:30 - 9:00 PM	Q&A		
9:00 PM	<b>Closing Comments</b>		



**Register Now** →

Visit at: [www.ccrnmd.com](http://www.ccrnmd.com)

This program has received unrestricted educational funding support from:

 **Gold:** Amgen, AstraZeneca  
 **Bronze:** Bayer, Merck

For inquiries regarding this program, please contact [info@ccrnmd.com](mailto:info@ccrnmd.com)